Veeva Systems
VEEV
$157.08
-5.70%
Veeva Systems Inc. is a global leader in providing cloud-based software solutions exclusively for the life sciences industry, with core products including Veeva CRM for customer relationship management and Veeva Vault for content management. The company has established itself as a dominant, best-of-breed platform, displacing legacy enterprise systems by leveraging deep domain expertise to address critical operating and regulatory requirements for its clients. The current investor narrative is sharply focused on a significant stock price correction, with shares down over 40% from recent highs, creating a debate between viewing this as a structural buying opportunity due to the company's entrenched niche and long-term growth runway versus a fundamental re-rating driven by growth deceleration concerns.…
VEEV
Veeva Systems
$157.08
Related headlines
VEEV 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Veeva Systems's 12-month outlook, with a consensus price target around $204.20 and implied upside of +30.0% versus the current price.
Average Target
$204.20
9 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
9
covering this stock
Price Range
$126 - $204
Analyst target range
Analyst coverage for Veeva is robust with 9 firms providing estimates, and the institutional ratings show a consensus that leans bullish, with recent actions including 'Buy' from Citigroup, TD Cowen, and Truist, and 'Overweight' from Piper Sandler and Wells Fargo, against a backdrop of several 'Neutral' or 'Equal Weight' ratings. The average revenue estimate for the coming period is $5.88 billion, with a tight range between $5.81 billion and $5.97 billion, indicating strong analyst conviction in the company's near-term financial trajectory, though a specific price target and implied upside are not calculable from the provided data. The target price range and the implications of high and low targets cannot be quantified due to missing average target price data, but the recent flurry of analyst activity in early March 2026, predominantly reiterating existing ratings, suggests the Street is closely monitoring the stock after its sharp decline but has not yet made major changes to its long-term thesis.
Bulls vs Bears: VEEV Investment Factors
The investment debate for Veeva Systems centers on whether its sharp 44% price correction represents a structural buying opportunity for a dominant, high-margin franchise, or a justified re-rating due to fundamental growth deceleration. Currently, the bear case holds stronger near-term evidence, as the persistent technical downtrend and clear sequential slowdown in revenue growth are concrete, observable data points that have driven the sell-off. However, the bull case is supported by the company's exceptional financial health, entrenched competitive position, and the significant valuation reset that has already occurred. The single most important tension is the resolution of the growth trajectory: if Veeva can stabilize and re-accelerate revenue growth above 16% while maintaining its ~30% net margins, the stock could see a powerful re-rating; conversely, a further deceleration into the low-teens would validate bearish concerns and likely lead to additional multiple compression.
Bullish
- Dominant Niche with High Margins: Veeva's entrenched position in the life sciences cloud software niche is evidenced by its superior gross margin of 74.46% and net margin of 29.21%, which are well above typical software industry averages. This profitability reflects pricing power and a best-of-breed product suite that is difficult to displace.
- Strong Balance Sheet & Cash Flow: The company has minimal financial risk with a debt-to-equity ratio of 0.013 and a current ratio of 4.89. It generates substantial free cash flow ($1.39B TTM), providing ample internal resources for growth and shareholder returns without reliance on external financing.
- Significant Valuation Contraction: The stock's trailing P/E has contracted from a recent peak of 57.86x to 36.72x, and the forward P/E of 17.60x suggests the market is pricing in a substantial earnings acceleration. This 44% decline from the 52-week high of $310.5 creates a potential entry point for a high-quality business.
- Analyst Conviction in Revenue Trajectory: Analyst consensus shows a tight revenue estimate range for the coming period ($5.81B to $5.97B), indicating strong conviction in the near-term financial path. Recent analyst activity in March 2026 has been predominantly reiterating bullish ratings, suggesting the Street sees the sell-off as overdone.
Bearish
- Clear Growth Deceleration Trend: Revenue growth has sequentially decelerated from 16.0% YoY in Q3 to 15.96% in Q4, following a multi-quarter pattern of moderation from the mid-teens. This trend raises concerns about the company's ability to sustain its historical growth rates and justify its premium valuation.
- Persistent Technical Downtrend: The stock is in a pronounced downtrend, down 41.28% over six months and 20.73% over three months, significantly underperforming the S&P 500 by -16.73% over three months. This persistent selling pressure indicates deep-seated investor concerns beyond simple market volatility.
- Premium Valuation Despite Correction: Even after the sharp decline, Veeva's trailing P/E of 36.72x and P/S of 10.44x likely command a significant premium to the broader software sector. The PEG ratio of 1.42 suggests the stock is not cheap relative to its growth, leaving it vulnerable to further multiple compression.
- Operating Margin Fluctuation: Operating margin declined from 32.15% in Q3 to 29.41% in Q4, indicating potential investment or cost pressures that could impact the path to profitability. This volatility in a key profitability metric introduces uncertainty into earnings forecasts.
VEEV Technical Analysis
The prevailing price trend is a pronounced and sustained downtrend, with the stock down 41.28% over the last six months and 23.20% over the past year. As of the latest close of $173.98, the stock is trading approximately 44% above its 52-week low of $168.14 but 44% below its 52-week high of $310.5, positioning it in the lower-middle portion of its annual range and suggesting it is recovering from deeply oversold levels but remains far from previous highs. Recent short-term momentum shows continued weakness, with the stock down 6.42% over the past month and 20.73% over the past three months, indicating that selling pressure has persisted and accelerated relative to the broader market, as evidenced by a relative strength of -16.73% over three months. Key technical support is firmly established at the 52-week low of $168.14, while major resistance lies at the 52-week high of $310.5; a sustained breakdown below $168 would signal a continuation of the bearish trend, whereas a recovery above the $200-$220 zone would be needed to suggest a meaningful reversal. With a beta of 1.103, the stock exhibits volatility moderately higher than the market, which has been amplified during this downtrend, as shown by a maximum drawdown of -43.83%.
Beta
1.10
1.10x market volatility
Max Drawdown
-48.7%
Largest decline past year
52-Week Range
$156-$311
Price range past year
Annual Return
-27.6%
Cumulative gain past year
| Period | VEEV Return | S&P 500 |
|---|---|---|
| 1m | -17.2% | +0.4% |
| 3m | -34.6% | -2.0% |
| 6m | -45.2% | +4.1% |
| 1y | -27.6% | +23.9% |
| ytd | -28.4% | -0.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VEEV Fundamental Analysis
Revenue growth remains healthy but shows signs of sequential deceleration; the most recent quarterly revenue for Q4 FY2026 was $835.95 million, representing a solid 15.96% year-over-year increase, yet this marks a slowdown from the 16.0% YoY growth in Q3 and follows a multi-quarter pattern of growth rates moderating from the mid-teens towards the low-teens. The company is highly profitable with robust margins, reporting net income of $244.20 million for the quarter and a net margin of 29.21%, while its gross margin of 74.46% reflects its premium software-as-a-service model; however, operating margins have shown some quarterly fluctuation, from 29.41% in Q4 down from 32.15% in Q3, indicating potential investment or cost pressures. The balance sheet is exceptionally strong with minimal financial risk, evidenced by a debt-to-equity ratio of just 0.013, a current ratio of 4.89 indicating ample liquidity, and substantial free cash flow generation of $1.39 billion on a trailing-twelve-month basis, which provides the company with significant internal resources to fund growth initiatives and shareholder returns without reliance on external financing.
Quarterly Revenue
$835951000.0B
2026-01
Revenue YoY Growth
+0.15%
YoY Comparison
Gross Margin
+0.74%
Latest Quarter
Free Cash Flow
$1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VEEV Overvalued?
Given the company's consistent profitability with net income of $244.20 million in its latest quarter, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio stands at 36.72x, while the forward PE is significantly lower at 17.60x, indicating the market is pricing in a substantial acceleration in earnings growth over the next twelve months. Compared to sector averages, Veeva's trailing PE of 36.72x and Price-to-Sales ratio of 10.44x likely command a premium, justified by its superior net margin of 28.44% and gross margin of 75.53%, which are well above typical software industry averages, reflecting its niche dominance and high-quality revenue model. Historically, the current trailing PE of 36.72x sits well below its own historical peaks seen in recent years, such as the 57.86x recorded in Q2 FY2026, suggesting the multiple has contracted significantly and may now be pricing in more conservative expectations, though it remains above the low-20s seen in earlier fiscal years.
PE
36.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 34x~117x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
35.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Veeva's primary financial risk is not solvency—its balance sheet is pristine—but rather growth sustainability to justify its valuation. The company's revenue growth has decelerated to 15.96% YoY, and any further slowdown below the low-teens could trigger significant multiple contraction given its forward P/E of 17.6x is predicated on earnings acceleration. While margins are robust, the quarterly fluctuation in operating margin (down nearly 300 bps QoQ) indicates potential cost pressures or increased investment needs that could dampen profitability. Revenue concentration in the life sciences sector, while a competitive moat, also creates dependency on biopharma capital expenditure cycles.
Market & Competitive Risks: The stock faces pronounced valuation compression risk, as its trailing P/E of 36.7x and P/S of 10.4x remain at a premium despite the correction. A sustained higher interest rate environment could continue to compress multiples for growth stocks like Veeva, as evidenced by its beta of 1.103 amplifying market downturns. Competitive risks, while mitigated by deep domain expertise, include potential encroachment from larger enterprise software vendors or niche startups. The recent underperformance relative to the S&P 500 by -45.4% over one year highlights severe sector rotation out of growth and into value or other defensive areas.
Worst-Case Scenario: The most damaging scenario involves a combination of a severe economic downturn that pressures biopharma IT budgets, coupled with Veeva's revenue growth decelerating into the single digits. This would lead to consecutive earnings misses, a wave of analyst downgrades, and a derating of the forward P/E towards 15x or lower. In this adverse scenario, the stock could realistically test and break below its 52-week low of $168.14, representing a downside of approximately -3.4% from the current price of $173.98. A more severe bear case, aligning with a max drawdown of -43.8%, could see the stock fall towards the $150-$160 range, implying a potential loss of -8% to -14% from current levels.